Pub Date : 2024-07-04DOI: 10.1186/s13550-024-01115-4
Neree Payan, Benoit Presles, Charles Coutant, Isabelle Desmoulins, Sylvain Ladoire, Françoise Beltjens, François Brunotte, Jean-Marc Vrigneaud, Alexandre Cochet
Background: The aim of this study is to investigate the added value of combining tumour blood flow (BF) and metabolism parameters, including texture features, with clinical parameters to predict, at baseline, the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with newly diagnosed breast cancer (BC).
Methods: One hundred and twenty-eight BC patients underwent a 18F-FDG PET/CT before any treatment. Tumour BF and metabolism parameters were extracted from first-pass dynamic and delayed PET images, respectively. Standard and texture features were extracted from BF and metabolic images. Prediction of pCR was performed using logistic regression, random forest and support vector classification algorithms. Models were built using clinical (C), clinical and metabolic (C+M) and clinical, metabolic and tumour BF (C+M+BF) information combined. Algorithms were trained on 80% of the dataset and tested on the remaining 20%. Univariate and multivariate features selections were carried out on the training dataset. A total of 50 shuffle splits were performed. The analysis was carried out on the whole dataset (HER2 and Triple Negative (TN)), and separately in HER2 (N=76) and TN (N=52) tumours.
Results: In the whole dataset, the highest classification performances were observed for C+M models, significantly (p-value<0.01) higher than C models and better than C+M+BF models (mean balanced accuracy of 0.66, 0.61, and 0.64 respectively). For HER2 tumours, equal performances were noted for C and C+M models, with performances higher than C+M+BF models (mean balanced accuracy of 0.64, and 0.61 respectively). Regarding TN tumours, the best classification results were reported for C+M models, with better performances than C and C+M+BF models but not significantly (mean balanced accuracy of 0.65, 0.63, and 0.62 respectively).
Conclusion: Baseline clinical data combined with global and texture tumour metabolism parameters assessed by 18F-FDG PET/CT provide a better prediction of pCR after NAC in patients with BC compared to clinical parameters alone for TN, and HER2 and TN tumours together. In contrast, adding BF parameters to the models did not improve prediction, regardless of the tumour subgroup analysed.
{"title":"Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.","authors":"Neree Payan, Benoit Presles, Charles Coutant, Isabelle Desmoulins, Sylvain Ladoire, Françoise Beltjens, François Brunotte, Jean-Marc Vrigneaud, Alexandre Cochet","doi":"10.1186/s13550-024-01115-4","DOIUrl":"10.1186/s13550-024-01115-4","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to investigate the added value of combining tumour blood flow (BF) and metabolism parameters, including texture features, with clinical parameters to predict, at baseline, the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with newly diagnosed breast cancer (BC).</p><p><strong>Methods: </strong>One hundred and twenty-eight BC patients underwent a <sup>18</sup>F-FDG PET/CT before any treatment. Tumour BF and metabolism parameters were extracted from first-pass dynamic and delayed PET images, respectively. Standard and texture features were extracted from BF and metabolic images. Prediction of pCR was performed using logistic regression, random forest and support vector classification algorithms. Models were built using clinical (C), clinical and metabolic (C+M) and clinical, metabolic and tumour BF (C+M+BF) information combined. Algorithms were trained on 80% of the dataset and tested on the remaining 20%. Univariate and multivariate features selections were carried out on the training dataset. A total of 50 shuffle splits were performed. The analysis was carried out on the whole dataset (HER2 and Triple Negative (TN)), and separately in HER2 (N=76) and TN (N=52) tumours.</p><p><strong>Results: </strong>In the whole dataset, the highest classification performances were observed for C+M models, significantly (p-value<0.01) higher than C models and better than C+M+BF models (mean balanced accuracy of 0.66, 0.61, and 0.64 respectively). For HER2 tumours, equal performances were noted for C and C+M models, with performances higher than C+M+BF models (mean balanced accuracy of 0.64, and 0.61 respectively). Regarding TN tumours, the best classification results were reported for C+M models, with better performances than C and C+M+BF models but not significantly (mean balanced accuracy of 0.65, 0.63, and 0.62 respectively).</p><p><strong>Conclusion: </strong>Baseline clinical data combined with global and texture tumour metabolism parameters assessed by <sup>18</sup>F-FDG PET/CT provide a better prediction of pCR after NAC in patients with BC compared to clinical parameters alone for TN, and HER2 and TN tumours together. In contrast, adding BF parameters to the models did not improve prediction, regardless of the tumour subgroup analysed.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11224181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03DOI: 10.1186/s13550-024-01121-6
Jae Hun Ahn, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Hee Seup Kil, Soon Jeong Kwon, Jae Yong Choi, Dae Yoon Chi, Yong Jin Lee
Background: N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson's disease (PD). 123I- and 18F-labeled FP-CIT has been used for PD diagnosis. However, preclinical studies evaluating [18F]FP-CIT as a potential diagnostic biomarker are scarce. Among translational research advancements from bench to bedside, translating preclinical findings into clinical practice is one-directional. The aim of this study is to employ a circular approach, beginning back from the preclinical stage, progressing to the supplementation of [18F]FP-CIT, and subsequently returning to clinical application. We investigated the pharmacokinetic properties of [18F]FP-CIT and its efficacy for PD diagnosis using murine models.
Results: Biodistribution, metabolite and excretion analyses were performed in mice and PD models were induced in rats using 6-hydroxydopamine (6-OHDA). The targeting efficiency of [18F]FP-CIT for the dopamine receptor was assessed through animal PET/CT imaging. Subsequently, correlation analysis was conducted between animal PET/CT imaging results and immunohistochemistry (IHC) targeting tyrosine hydroxylase. Rapid circulation was confirmed after [18F]FP-CIT injection. [18F]FP-CIT reached the highest uptake of 23.50 ± 12.46%ID/g in the striatum 1 min after injection, and it was rapidly excreted within 60 min. The major metabolic organs of [18F]FP-CIT were confirmed to be the intestines, liver, and kidneys. Its uptake in the intestine was approximately 5% ID/g. The uptake in the liver gradually increased, with excretion beginning after reaching a maximum after 60 min. The kidneys exhibited rapid elimination after 10 min. In the excretion study, rapid elimination was verified, with 21.46 ± 9.53% of the compound excreted within a 6 h period. Additionally, the efficacy of [18F]FP-CIT PET was demonstrated in the PD model, with a high correlation with IHC for both the absolute value (R = 0.803, p = 0.0017) and the ratio value (R = 0.973, p = 0.0011).
Conclusions: This study fills the gap regarding insufficient preclinical studies on [18F]FP-CIT, including its ADME, metabolites, and efficiency. The pharmacological results, including accurate diagnosis, rapid circulation, and [18F]FP-CIT excretion, provide complementary evidence that [18F]FP-CIT can be used safely and efficiently to diagnose PD in clinics, although it is already used in clinics.
{"title":"Preclinical evaluation of [<sup>18</sup>F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson's disease: pharmacokinetic and efficacy analysis.","authors":"Jae Hun Ahn, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Hee Seup Kil, Soon Jeong Kwon, Jae Yong Choi, Dae Yoon Chi, Yong Jin Lee","doi":"10.1186/s13550-024-01121-6","DOIUrl":"10.1186/s13550-024-01121-6","url":null,"abstract":"<p><strong>Background: </strong>N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson's disease (PD). <sup>123</sup>I- and <sup>18</sup>F-labeled FP-CIT has been used for PD diagnosis. However, preclinical studies evaluating [<sup>18</sup>F]FP-CIT as a potential diagnostic biomarker are scarce. Among translational research advancements from bench to bedside, translating preclinical findings into clinical practice is one-directional. The aim of this study is to employ a circular approach, beginning back from the preclinical stage, progressing to the supplementation of [<sup>18</sup>F]FP-CIT, and subsequently returning to clinical application. We investigated the pharmacokinetic properties of [<sup>18</sup>F]FP-CIT and its efficacy for PD diagnosis using murine models.</p><p><strong>Results: </strong>Biodistribution, metabolite and excretion analyses were performed in mice and PD models were induced in rats using 6-hydroxydopamine (6-OHDA). The targeting efficiency of [<sup>18</sup>F]FP-CIT for the dopamine receptor was assessed through animal PET/CT imaging. Subsequently, correlation analysis was conducted between animal PET/CT imaging results and immunohistochemistry (IHC) targeting tyrosine hydroxylase. Rapid circulation was confirmed after [<sup>18</sup>F]FP-CIT injection. [<sup>18</sup>F]FP-CIT reached the highest uptake of 23.50 ± 12.46%ID/g in the striatum 1 min after injection, and it was rapidly excreted within 60 min. The major metabolic organs of [<sup>18</sup>F]FP-CIT were confirmed to be the intestines, liver, and kidneys. Its uptake in the intestine was approximately 5% ID/g. The uptake in the liver gradually increased, with excretion beginning after reaching a maximum after 60 min. The kidneys exhibited rapid elimination after 10 min. In the excretion study, rapid elimination was verified, with 21.46 ± 9.53% of the compound excreted within a 6 h period. Additionally, the efficacy of [<sup>18</sup>F]FP-CIT PET was demonstrated in the PD model, with a high correlation with IHC for both the absolute value (R = 0.803, p = 0.0017) and the ratio value (R = 0.973, p = 0.0011).</p><p><strong>Conclusions: </strong>This study fills the gap regarding insufficient preclinical studies on [<sup>18</sup>F]FP-CIT, including its ADME, metabolites, and efficiency. The pharmacological results, including accurate diagnosis, rapid circulation, and [<sup>18</sup>F]FP-CIT excretion, provide complementary evidence that [<sup>18</sup>F]FP-CIT can be used safely and efficiently to diagnose PD in clinics, although it is already used in clinics.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-26DOI: 10.1186/s13550-024-01119-0
Sarah Chehri, Otto Mølby Henriksen, Lisbeth Marner, Mette Christensen, Aida Muhic, Hans Skovgaard Poulsen, Ian Law
Background: O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography ([18F]FET PET) scanning is used in routine clinical management and evaluation of gliomas with a recommended 4 h prior fasting. Knowledge of test-retest variation of [18F]FET PET imaging uptake metrics and the impact of accidental protein intake can be critical for interpretation. The aim of this study was to investigate the repeatability of [18F]FET-PET metrics and to assess the impact of protein-intake prior to [18F]FET PET scanning of gliomas.
Results: Test-retest variability in the non-protein group was good with absolute (and relative) upper and lower limits of agreement of + 0.15 and - 0.13 (+ 9.7% and - 9.0%) for mean tumour-to-background ratio (TBRmean), + 0.43 and - 0.28 (+ 19.6% and - 11.8%) for maximal tumour-to-background ratio (TBRmax), and + 2.14 cm3 and - 1.53 ml (+ 219.8% and - 57.3%) for biological tumour volume (BTV). Variation was lower for uptake ratios than for BTV. Protein intake was associated with a 27% increase in the total sum of plasma concentration of the L-type amino acid transporter 1 (LAT1) relevant amino acids and with decreased standardized uptake value (SUV) in both healthy appearing background brain tissue (mean SUV - 25%) and in tumour (maximal SUV - 14%). Oral intake of 24 g of protein 1 h prior to injection of tracer tended to increase variability, but the effects on derived tumour metrics TBRmean and TBRmax were only borderline significant, and changes generally within the variability observed in the group with no protein intake.
Conclusion: The test-retest repeatability was found to be good, and better for TBRmax and TBRmean than BTV, with the methodological limitation that tumour growth may have influenced results. Oral intake of 24 g of protein one hour before a [18F]FET PET scan decreases uptake of [18F]FET in both tumour and in healthy appearing brain, with no clinically significant difference on the most commonly used tumour metrics.
背景:O-(2-[18F]氟乙基)-L-酪氨酸正电子发射断层扫描([18F]FET PET)扫描用于神经胶质瘤的常规临床管理和评估,建议在扫描前禁食 4 小时。了解[18F]FET PET 成像摄取指标的测试-重复变异以及意外摄入蛋白质的影响对解释至关重要。本研究旨在调查[18F]FET-PET指标的重复性,并评估胶质瘤[18F]FET PET扫描前摄入蛋白质的影响:结果:非蛋白质组的测试-重复变异性良好,平均肿瘤-背景比值(TBRmean)的绝对(和相对)上限和下限分别为+ 0.15和- 0.13(+ 9.7%和- 9.0%),+ 0.43和- 0.28(+ 19.6%和- 11.8%),生物肿瘤体积(BTV)分别为+ 2.14立方厘米和- 1.53毫升(+ 219.8%和- 57.3%)。摄取率的变化低于生物肿瘤体积的变化。摄入蛋白质可使血浆中 L 型氨基酸转运体 1(LAT1)相关氨基酸的总浓度增加 27%,并降低健康背景脑组织(平均 SUV - 25%)和肿瘤(最大 SUV - 14%)的标准化摄取值(SUV)。在注射示踪剂前1小时口服24克蛋白质有增加可变性的趋势,但对衍生肿瘤指标TBRmean和TBRmax的影响仅有边缘显著性,其变化一般在未摄入蛋白质组的可变性范围内:结论:试验重复性良好,TBRmax和TBRmean的重复性优于BTV,但方法上的局限性是肿瘤生长可能会影响结果。在进行[18F]FET PET 扫描前一小时口服 24 克蛋白质会降低肿瘤和健康大脑对[18F]FET 的摄取,但在最常用的肿瘤指标上没有临床显著差异。
{"title":"A prospective clinical study of the influence of oral protein intake on [<sup>18</sup>F]FET-PET uptake and test-retest repeatability in glioma.","authors":"Sarah Chehri, Otto Mølby Henriksen, Lisbeth Marner, Mette Christensen, Aida Muhic, Hans Skovgaard Poulsen, Ian Law","doi":"10.1186/s13550-024-01119-0","DOIUrl":"10.1186/s13550-024-01119-0","url":null,"abstract":"<p><strong>Background: </strong>O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine positron emission tomography ([<sup>18</sup>F]FET PET) scanning is used in routine clinical management and evaluation of gliomas with a recommended 4 h prior fasting. Knowledge of test-retest variation of [<sup>18</sup>F]FET PET imaging uptake metrics and the impact of accidental protein intake can be critical for interpretation. The aim of this study was to investigate the repeatability of [<sup>18</sup>F]FET-PET metrics and to assess the impact of protein-intake prior to [<sup>18</sup>F]FET PET scanning of gliomas.</p><p><strong>Results: </strong>Test-retest variability in the non-protein group was good with absolute (and relative) upper and lower limits of agreement of + 0.15 and - 0.13 (+ 9.7% and - 9.0%) for mean tumour-to-background ratio (TBR<sub>mean</sub>), + 0.43 and - 0.28 (+ 19.6% and - 11.8%) for maximal tumour-to-background ratio (TBR<sub>max</sub>), and + 2.14 cm<sup>3</sup> and - 1.53 ml (+ 219.8% and - 57.3%) for biological tumour volume (BTV). Variation was lower for uptake ratios than for BTV. Protein intake was associated with a 27% increase in the total sum of plasma concentration of the L-type amino acid transporter 1 (LAT1) relevant amino acids and with decreased standardized uptake value (SUV) in both healthy appearing background brain tissue (mean SUV - 25%) and in tumour (maximal SUV - 14%). Oral intake of 24 g of protein 1 h prior to injection of tracer tended to increase variability, but the effects on derived tumour metrics TBR<sub>mean</sub> and TBR<sub>max</sub> were only borderline significant, and changes generally within the variability observed in the group with no protein intake.</p><p><strong>Conclusion: </strong>The test-retest repeatability was found to be good, and better for TBR<sub>max</sub> and TBR<sub>mean</sub> than BTV, with the methodological limitation that tumour growth may have influenced results. Oral intake of 24 g of protein one hour before a [<sup>18</sup>F]FET PET scan decreases uptake of [<sup>18</sup>F]FET in both tumour and in healthy appearing brain, with no clinically significant difference on the most commonly used tumour metrics.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Paraquat (PQ) -induced pulmonary fibrosis poses a significant medical challenge due to limited treatment options and high mortality rates. Consequently, there is an urgent need for early diagnosis and accurate staging to facilitate appropriate treatment strategies. In this study, we assessed the diagnostic potential of [18F]F-FAPI-42 PET/CT imaging for early detection and disease staging in a rat model of PQ-induced lung fibrosis.
Methods: After administering 80 mg/kg of PQ orally to Sprague-Dawley rats, we intravenously injected 3-3.5 MBq of [18F]F-FAPI-42 on day 7, 14, and 21 post-dosing. Dynamic PET/CT imaging was carried out for one hour immediately after the administration of [18F]F-FAPI-42. Subsequently, the lung tissues were collected for Hematoxylin and Eosin (HE) staining, Masson's trichrome staining, and NOTA-FAPI-04-MB fluorescent probe staining. Data analysis was performed using the Imalytics preclinical software, and the mean standardized uptake value (SUVmean) was calculated.
Results: PET signals revealed that in areas with evident lesions on CT, the SUVmean on day 14 was significantly higher than on day 7 and 21, indicating that changes in fibrosis activity levels contribute to the staging of pulmonary fibrosis. Additionally, the NOTA-FAPI-04-MB fluorescent probe staining also demonstrated the most pronounced probe uptake on day 14. In regions without apparent lesions on CT, the SUVmean gradually increased from day 7 to day 21, reflecting ongoing fibrotic activity. Moreover, HE staining and Masson's trichrome staining did not reveal pulmonary fibrosis, while PET imaging was able to detect it, serving the purpose of early diagnosis. At 30 min and 60 min, the target-to-background ratio (TBR) of the PQ groups on day 7, 14, and 21 was significantly higher than the control group, suggesting a high specificity of [18F]F-FAPI-42 binding to activated fibroblasts.
Conclusion: [18F]F-FAPI-42 PET/CT imaging enables early diagnosis and staging of PQ-induced pulmonary fibrosis, demonstrating its feasibility and potential for characterizing early disease stages.
{"title":"Early diagnosis and staging of paraquat-induced pulmonary fibrosis using [<sup>18</sup>F]F-FAPI-42 PET/CT imaging.","authors":"Dimei Zhang, Yusheng Shi, Jiangwei Kong, Na Chen, Guiting Li, Mingfang Wang, Guoxia Zhang, Chuangyan Zhai","doi":"10.1186/s13550-024-01118-1","DOIUrl":"10.1186/s13550-024-01118-1","url":null,"abstract":"<p><strong>Background: </strong>Paraquat (PQ) -induced pulmonary fibrosis poses a significant medical challenge due to limited treatment options and high mortality rates. Consequently, there is an urgent need for early diagnosis and accurate staging to facilitate appropriate treatment strategies. In this study, we assessed the diagnostic potential of [<sup>18</sup>F]F-FAPI-42 PET/CT imaging for early detection and disease staging in a rat model of PQ-induced lung fibrosis.</p><p><strong>Methods: </strong>After administering 80 mg/kg of PQ orally to Sprague-Dawley rats, we intravenously injected 3-3.5 MBq of [<sup>18</sup>F]F-FAPI-42 on day 7, 14, and 21 post-dosing. Dynamic PET/CT imaging was carried out for one hour immediately after the administration of [<sup>18</sup>F]F-FAPI-42. Subsequently, the lung tissues were collected for Hematoxylin and Eosin (HE) staining, Masson's trichrome staining, and NOTA-FAPI-04-MB fluorescent probe staining. Data analysis was performed using the Imalytics preclinical software, and the mean standardized uptake value (SUV<sub>mean</sub>) was calculated.</p><p><strong>Results: </strong>PET signals revealed that in areas with evident lesions on CT, the SUV<sub>mean</sub> on day 14 was significantly higher than on day 7 and 21, indicating that changes in fibrosis activity levels contribute to the staging of pulmonary fibrosis. Additionally, the NOTA-FAPI-04-MB fluorescent probe staining also demonstrated the most pronounced probe uptake on day 14. In regions without apparent lesions on CT, the SUV<sub>mean</sub> gradually increased from day 7 to day 21, reflecting ongoing fibrotic activity. Moreover, HE staining and Masson's trichrome staining did not reveal pulmonary fibrosis, while PET imaging was able to detect it, serving the purpose of early diagnosis. At 30 min and 60 min, the target-to-background ratio (TBR) of the PQ groups on day 7, 14, and 21 was significantly higher than the control group, suggesting a high specificity of [<sup>18</sup>F]F-FAPI-42 binding to activated fibroblasts.</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]F-FAPI-42 PET/CT imaging enables early diagnosis and staging of PQ-induced pulmonary fibrosis, demonstrating its feasibility and potential for characterizing early disease stages.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-17DOI: 10.1186/s13550-024-01117-2
Mengfei Xiong, Mark Lubberink, Lieuwe Appel, Xiaotian Tsong Fang, Torsten Danfors, Eva Kumlien, Gunnar Antoni
Background: In preclinical studies, the positron emission tomography (PET) imaging with [11C]UCB-A provided promising results for imaging synaptic vesicle protein 2A (SV2A) as a proxy for synaptic density. This paper reports the first-in-human [11C]UCB-A PET study to characterise its kinetics in healthy subjects and further evaluate SV2A-specific binding.
Results: Twelve healthy subjects underwent 90-min baseline [11C]UCB-A scans with PET/MRI, with two subjects participating in an additional blocking scan with the same scanning procedure after a single dose of levetiracetam (1500 mg). Our results indicated abundant [11C]UCB-A brain uptake across all cortical regions, with slow elimination. Kinetic modelling of [11C]UCB-A PET using various compartment models suggested that the irreversible two-tissue compartment model best describes the kinetics of the radioactive tracer. Accordingly, the Patlak graphical analysis was used to simplify the analysis. The estimated SV2A occupancy determined by the Lassen plot was around 66%. Significant specific binding at baseline and comparable binding reduction as grey matter precludes the use of centrum semiovale as reference tissue.
Conclusions: [11C]UCB-A PET imaging enables quantifying SV2A in vivo. However, its slow kinetics require a long scan duration, which is impractical with the short half-life of carbon-11. Consequently, the slow kinetics and complicated quantification methods may restrict its use in humans.
背景:在临床前研究中,[11C]UCB-A 正电子发射断层扫描(PET)成像为突触囊泡蛋白 2A (SV2A)作为突触密度的替代物提供了很好的成像结果。本文报告了首次人体[11C]UCB-A PET研究,以确定其在健康受试者体内的动力学特征,并进一步评估 SV2A 的特异性结合:12名健康受试者接受了90分钟的PET/MRI[11C]UCB-A基线扫描,其中两名受试者在服用单剂量左乙拉西坦(1500毫克)后参加了额外的阻断扫描,扫描过程相同。我们的研究结果表明,大脑皮层所有区域都摄取了大量的[11C]UCB-A,且消除速度较慢。使用各种区室模型对[11C]UCB-A PET进行动力学建模表明,不可逆的双组织区室模型最能描述放射性示踪剂的动力学。因此,采用 Patlak 图形分析法来简化分析。拉森图确定的 SV2A 占位率估计约为 66%。基线时的特异性结合和与灰质相当的结合减少排除了将半叶中心作为参考组织的可能性:结论:[11C]UCB-A PET 成像可量化体内 SV2A。结论:[11C]UCB-A PET 成像可量化体内 SV2A,但其缓慢的动力学要求较长的扫描时间,而碳-11 的半衰期较短,这是不现实的。因此,缓慢的动力学和复杂的量化方法可能会限制其在人体中的应用。
{"title":"Evaluation of [<sup>11</sup>C]UCB-A positron emission tomography in human brains.","authors":"Mengfei Xiong, Mark Lubberink, Lieuwe Appel, Xiaotian Tsong Fang, Torsten Danfors, Eva Kumlien, Gunnar Antoni","doi":"10.1186/s13550-024-01117-2","DOIUrl":"10.1186/s13550-024-01117-2","url":null,"abstract":"<p><strong>Background: </strong>In preclinical studies, the positron emission tomography (PET) imaging with [<sup>11</sup>C]UCB-A provided promising results for imaging synaptic vesicle protein 2A (SV2A) as a proxy for synaptic density. This paper reports the first-in-human [<sup>11</sup>C]UCB-A PET study to characterise its kinetics in healthy subjects and further evaluate SV2A-specific binding.</p><p><strong>Results: </strong>Twelve healthy subjects underwent 90-min baseline [<sup>11</sup>C]UCB-A scans with PET/MRI, with two subjects participating in an additional blocking scan with the same scanning procedure after a single dose of levetiracetam (1500 mg). Our results indicated abundant [<sup>11</sup>C]UCB-A brain uptake across all cortical regions, with slow elimination. Kinetic modelling of [<sup>11</sup>C]UCB-A PET using various compartment models suggested that the irreversible two-tissue compartment model best describes the kinetics of the radioactive tracer. Accordingly, the Patlak graphical analysis was used to simplify the analysis. The estimated SV2A occupancy determined by the Lassen plot was around 66%. Significant specific binding at baseline and comparable binding reduction as grey matter precludes the use of centrum semiovale as reference tissue.</p><p><strong>Conclusions: </strong>[<sup>11</sup>C]UCB-A PET imaging enables quantifying SV2A in vivo. However, its slow kinetics require a long scan duration, which is impractical with the short half-life of carbon-11. Consequently, the slow kinetics and complicated quantification methods may restrict its use in humans.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11183037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-16DOI: 10.1186/s13550-024-01116-3
Ling Xiao, Zhihui Fang, Yongxiang Tang, Yanyan Sun, Zehua Zhu, Jian Li, Ming Zhou, Nengan Yang, Kai Zheng, Shuo Hu
Background: Studies on single-target PET imaging of gastrin-releasing peptide receptor (GRPR), prostate-specific membrane antigen (PSMA), or neurotensin receptor 1(NTR1) have been reported. However, the performance of these three targets in the progression of PCa remains unclear. Our study aims to compare the expression of GRPR, PSMA, and NTR1 in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer (PCa), and lymph node metastasis. We synthesized molecular probes targeting the markers to achieve a non-invasive precise detection of PCa patients with PET/CT imaging.
Methods: In this study, the expression of GRPR, PSMA, and NTR1 was evaluated by immunohistochemistry in 34 PIN, 171 PCa, and 22 lymph node metastasis tissues of patients. The correlation between their expression and the clinicopathological parameters of PCa patients was assessed. Sixteen PCa patients with different Gleason scores (GS) underwent dual-tracer (68Ga-NOTA-RM26 and 68Ga-NOTA-PSMA617) PET/CT.
Results: In the PIN stage, the expression of GRPR was significantly higher than that of PSMA and NTR1 (P < 0.001), while NTR1 expression was significantly higher than PSMA and GRPR expression in primary PCa (P = 0.001). High PSMA expression in PCa patients was associated with shorter progression-free survival (P = 0.037) and overall survival (P = 0.035). PCa patients with high GS had higher tumor uptake of 68Ga-NOTA-PSMA617 than those with low GS (P = 0.001), while PCa patients with low GS had higher tumor uptake of 68Ga-NOTA-RM26 than those with high GS (P = 0.001).
Conclusions: This study presents three novel biomarkers (PSMA, GRPR, and NTR1) as imaging agents for PET/CT, and may offer a promising approach for non-invasive precise detection and Gleason grade prediction of PCa patients.
{"title":"Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis.","authors":"Ling Xiao, Zhihui Fang, Yongxiang Tang, Yanyan Sun, Zehua Zhu, Jian Li, Ming Zhou, Nengan Yang, Kai Zheng, Shuo Hu","doi":"10.1186/s13550-024-01116-3","DOIUrl":"10.1186/s13550-024-01116-3","url":null,"abstract":"<p><strong>Background: </strong>Studies on single-target PET imaging of gastrin-releasing peptide receptor (GRPR), prostate-specific membrane antigen (PSMA), or neurotensin receptor 1(NTR1) have been reported. However, the performance of these three targets in the progression of PCa remains unclear. Our study aims to compare the expression of GRPR, PSMA, and NTR1 in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer (PCa), and lymph node metastasis. We synthesized molecular probes targeting the markers to achieve a non-invasive precise detection of PCa patients with PET/CT imaging.</p><p><strong>Methods: </strong>In this study, the expression of GRPR, PSMA, and NTR1 was evaluated by immunohistochemistry in 34 PIN, 171 PCa, and 22 lymph node metastasis tissues of patients. The correlation between their expression and the clinicopathological parameters of PCa patients was assessed. Sixteen PCa patients with different Gleason scores (GS) underwent dual-tracer (<sup>68</sup>Ga-NOTA-RM26 and <sup>68</sup>Ga-NOTA-PSMA617) PET/CT.</p><p><strong>Results: </strong>In the PIN stage, the expression of GRPR was significantly higher than that of PSMA and NTR1 (P < 0.001), while NTR1 expression was significantly higher than PSMA and GRPR expression in primary PCa (P = 0.001). High PSMA expression in PCa patients was associated with shorter progression-free survival (P = 0.037) and overall survival (P = 0.035). PCa patients with high GS had higher tumor uptake of <sup>68</sup>Ga-NOTA-PSMA617 than those with low GS (P = 0.001), while PCa patients with low GS had higher tumor uptake of <sup>68</sup>Ga-NOTA-RM26 than those with high GS (P = 0.001).</p><p><strong>Conclusions: </strong>This study presents three novel biomarkers (PSMA, GRPR, and NTR1) as imaging agents for PET/CT, and may offer a promising approach for non-invasive precise detection and Gleason grade prediction of PCa patients.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11180645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-13DOI: 10.1186/s13550-024-01114-5
Richard Aarnio, Anna Kirjavainen, Johan Rajander, Sarita Forsback, Kari Kalliokoski, Pirjo Nuutila, Zvonko Milicevic, Tamer Coskun, Axel Haupt, Iina Laitinen, Merja Haaparanta-Solin
Background: Fatty acid uptake can be measured using PET and 14-(R,S)-[18F]fluoro-6-thia-heptadecanoic acid ([18F]FTHA). However, the relatively rapid rate of [18F]FTHA metabolism significantly affects kinetic modeling of tissue uptake. Thus, there is a need for accurate chromatographic methods to analyze the unmetabolized [18F]FTHA (parent fraction). Here we present a new radiometabolite analysis (RMA) method, with comparison to a previous method for parent fraction analysis, and its use in a test-retest clinical study under fasting and postprandial conditions. We developed a new thin-layer chromatography (TLC) RMA method for analysis of [18F]FTHA parent fraction and its radiometabolites from plasma, by testing stationary phases and eluent combinations. Next, we analyzed [18F]FTHA, its radiometabolites, and plasma radioactivity from subjects participating in a clinical study. A total of 17 obese or overweight participants were dosed with [18F]FTHA twice under fasting, and twice under postprandial conditions and plasma samples were obtained between 14 min (mean of first sample) and 72 min (mean of last sample) post-injection. Aliquots of 70 plasma samples were analyzed using both methods, enabling head-to-head comparisons. We performed test-retest and group comparisons of the parent fraction and plasma radioactivity.
Results: The new TLC method separated seven [18F]FTHA radiometabolite peaks, while the previous method separated three. The new method revealed at least one radiometabolite that was not previously separable from [18F]FTHA. From the plasma samples, the mean parent fraction value was on average 7.2 percentage points lower with the new method, compared to the previous method. Repeated [18F]FTHA investigations on the same subject revealed reproducible plasma SUV and parent fractions, with different kinetics between the fasted and postprandial conditions.
Conclusions: The newly developed improved radio-TLC method for [18F]FTHA RMA enables accurate parent fraction correction, which is required to obtain quantitative data for modelling [18F]FTHA PET data. Our test-retest study of fasted and postprandial conditions showed robust reproducibility, and revealed clear differences in the [18F]FTHA metabolic rate under different study settings.
{"title":"New improved radiometabolite analysis method for [<sup>18</sup>F]FTHA from human plasma: a test-retest study with postprandial and fasting state.","authors":"Richard Aarnio, Anna Kirjavainen, Johan Rajander, Sarita Forsback, Kari Kalliokoski, Pirjo Nuutila, Zvonko Milicevic, Tamer Coskun, Axel Haupt, Iina Laitinen, Merja Haaparanta-Solin","doi":"10.1186/s13550-024-01114-5","DOIUrl":"10.1186/s13550-024-01114-5","url":null,"abstract":"<p><strong>Background: </strong>Fatty acid uptake can be measured using PET and 14-(R,S)-[<sup>18</sup>F]fluoro-6-thia-heptadecanoic acid ([<sup>18</sup>F]FTHA). However, the relatively rapid rate of [<sup>18</sup>F]FTHA metabolism significantly affects kinetic modeling of tissue uptake. Thus, there is a need for accurate chromatographic methods to analyze the unmetabolized [<sup>18</sup>F]FTHA (parent fraction). Here we present a new radiometabolite analysis (RMA) method, with comparison to a previous method for parent fraction analysis, and its use in a test-retest clinical study under fasting and postprandial conditions. We developed a new thin-layer chromatography (TLC) RMA method for analysis of [<sup>18</sup>F]FTHA parent fraction and its radiometabolites from plasma, by testing stationary phases and eluent combinations. Next, we analyzed [<sup>18</sup>F]FTHA, its radiometabolites, and plasma radioactivity from subjects participating in a clinical study. A total of 17 obese or overweight participants were dosed with [<sup>18</sup>F]FTHA twice under fasting, and twice under postprandial conditions and plasma samples were obtained between 14 min (mean of first sample) and 72 min (mean of last sample) post-injection. Aliquots of 70 plasma samples were analyzed using both methods, enabling head-to-head comparisons. We performed test-retest and group comparisons of the parent fraction and plasma radioactivity.</p><p><strong>Results: </strong>The new TLC method separated seven [<sup>18</sup>F]FTHA radiometabolite peaks, while the previous method separated three. The new method revealed at least one radiometabolite that was not previously separable from [<sup>18</sup>F]FTHA. From the plasma samples, the mean parent fraction value was on average 7.2 percentage points lower with the new method, compared to the previous method. Repeated [<sup>18</sup>F]FTHA investigations on the same subject revealed reproducible plasma SUV and parent fractions, with different kinetics between the fasted and postprandial conditions.</p><p><strong>Conclusions: </strong>The newly developed improved radio-TLC method for [<sup>18</sup>F]FTHA RMA enables accurate parent fraction correction, which is required to obtain quantitative data for modelling [<sup>18</sup>F]FTHA PET data. Our test-retest study of fasted and postprandial conditions showed robust reproducibility, and revealed clear differences in the [<sup>18</sup>F]FTHA metabolic rate under different study settings.</p><p><strong>Trial registration: </strong>EudraCT No: 2020-005211-48, 04Feb2021; and Clinical Trials registry NCT05132335, 29Oct2021, URL: https://classic.</p><p><strong>Clinicaltrials: </strong>gov/ct2/show/NCT05132335 .</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-13DOI: 10.1186/s13550-024-01112-7
Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Steven G DuBois, Nicole Nasholm, Daphne Haas-Kogan, Katherine K Matthay, William A Weiss, Clay Gustafson, Youngho Seo
Background: Neuroblastoma is the most common extra-cranial pediatric solid tumor. 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical highly specific for neuroblastoma tumors, providing potent radiotherapy to widely metastatic disease. Aurora kinase A (AURKA) plays a role in mitosis and stabilization of the MYCN protein in neuroblastoma. We aimed to study the impact of AURKA inhibitors on DNA damage and tumor cell death in combination with 131I-MIBG therapy in a pre-clinical model of high-risk neuroblastoma.
Results: Using an in vivo model of high-risk neuroblastoma, we demonstrated a marked combinatorial effect of 131I-MIBG and alisertib on tumor growth. In MYCN amplified cell lines, the combination of radiation and an AURKA A inhibitor increased DNA damage and apoptosis and decreased MYCN protein levels.
Conclusion: The combination of AURKA inhibition with 131I-MIBG treatment is active in resistant neuroblastoma models.
背景:神经母细胞瘤是最常见的颅外儿科实体瘤。131I-甲碘代苄基胍(MIBG)是一种对神经母细胞瘤肿瘤具有高度特异性的靶向放射性药物,可为广泛转移性疾病提供有效的放射治疗。极光激酶 A(AURKA)在神经母细胞瘤的有丝分裂和 MYCN 蛋白的稳定过程中发挥作用。我们的目的是在高危神经母细胞瘤临床前模型中研究 AURKA 抑制剂与 131I-MIBG 联合治疗对 DNA 损伤和肿瘤细胞死亡的影响:我们利用高危神经母细胞瘤体内模型,证实了 131I-MIBG 和 alisertib 对肿瘤生长的显著联合效应。在 MYCN 扩增的细胞系中,辐射和 AURKA A 抑制剂的联合作用增加了 DNA 损伤和细胞凋亡,降低了 MYCN 蛋白水平:结论:AURKA抑制剂与131I-MIBG联合治疗对耐药神经母细胞瘤模型有积极作用。
{"title":"Aurora Kinase A inhibition enhances DNA damage and tumor cell death with <sup>131</sup>I-MIBG therapy in high-risk neuroblastoma.","authors":"Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Steven G DuBois, Nicole Nasholm, Daphne Haas-Kogan, Katherine K Matthay, William A Weiss, Clay Gustafson, Youngho Seo","doi":"10.1186/s13550-024-01112-7","DOIUrl":"10.1186/s13550-024-01112-7","url":null,"abstract":"<p><strong>Background: </strong>Neuroblastoma is the most common extra-cranial pediatric solid tumor. <sup>131</sup>I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical highly specific for neuroblastoma tumors, providing potent radiotherapy to widely metastatic disease. Aurora kinase A (AURKA) plays a role in mitosis and stabilization of the MYCN protein in neuroblastoma. We aimed to study the impact of AURKA inhibitors on DNA damage and tumor cell death in combination with <sup>131</sup>I-MIBG therapy in a pre-clinical model of high-risk neuroblastoma.</p><p><strong>Results: </strong>Using an in vivo model of high-risk neuroblastoma, we demonstrated a marked combinatorial effect of <sup>131</sup>I-MIBG and alisertib on tumor growth. In MYCN amplified cell lines, the combination of radiation and an AURKA A inhibitor increased DNA damage and apoptosis and decreased MYCN protein levels.</p><p><strong>Conclusion: </strong>The combination of AURKA inhibition with <sup>131</sup>I-MIBG treatment is active in resistant neuroblastoma models.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-29DOI: 10.1186/s13550-024-01110-9
Jeremy Godefroy, Raphael Godefroy, Koral Vedder, Yair Altura, Alexandre Chicheportiche, Simona Ben-Haim, Gal Goldstein
Background: F-18-flurodeoxyglucose (FDG) PET/CT is routinely used for staging, evaluation of response to treatment and follow-up of most pediatric malignancies. Cervical lymph nodes can be involved in some pediatric malignancies, but increased uptake in non-malignant cervical lymph nodes is not exceptional in this population. The aim of the present study is to identify predictors of the maximum uptake in non-malignant cervical lymph nodes in the pediatric population.
Methods: 191 FDG PET/CT studies of pediatric patients without malignant involvement of cervical lymph nodes were retrospectively reviewed. The maximal Standard Uptake Value in the hottest cervical lymph node (SUVmaxCLN), as well as demographic, technical and imaging variables were recorded. The predictive effect of those variables on SUVmaxCLN was estimated using linear regression models.
Results: Increased FDG activity in cervical nodes was observed in 136/191 studies (71%). The mean SUVmaxCLN was 2.2 ± 1.3. Ipsilateral palatine tonsil SUVmax, mean liver uptake, and treatment status were all statistically significant predictors of SUVmaxCLN. However, in multivariate regression analysis, only ipsilateral palatine tonsil SUVmax was found to be significant. In addition, SUVmaxCLN was greater than the mean liver uptake in 50% of all studies. This proportion was higher in younger children, reaching 77% of studies of children younger than six years.
Conclusion: SUVmax in ipsilateral palatine tonsil is a strong predictor of the maximal uptake value of non-malignant cervical lymph nodes in children. The intensity of uptake in non-malignant cervical lymph nodes is frequently higher than liver uptake in children, and this tendency increases for younger patients.
Trial was registered: In the internal hospital registry under TRN 0209-22-HMO on date 23.04.2022.
{"title":"Distribution and predictors of F-18-FDG uptake values of non-malignant cervical lymph nodes in pediatric patients.","authors":"Jeremy Godefroy, Raphael Godefroy, Koral Vedder, Yair Altura, Alexandre Chicheportiche, Simona Ben-Haim, Gal Goldstein","doi":"10.1186/s13550-024-01110-9","DOIUrl":"10.1186/s13550-024-01110-9","url":null,"abstract":"<p><strong>Background: </strong>F-18-flurodeoxyglucose (FDG) PET/CT is routinely used for staging, evaluation of response to treatment and follow-up of most pediatric malignancies. Cervical lymph nodes can be involved in some pediatric malignancies, but increased uptake in non-malignant cervical lymph nodes is not exceptional in this population. The aim of the present study is to identify predictors of the maximum uptake in non-malignant cervical lymph nodes in the pediatric population.</p><p><strong>Methods: </strong>191 FDG PET/CT studies of pediatric patients without malignant involvement of cervical lymph nodes were retrospectively reviewed. The maximal Standard Uptake Value in the hottest cervical lymph node (SUVmax<sub>CLN</sub>), as well as demographic, technical and imaging variables were recorded. The predictive effect of those variables on SUVmax<sub>CLN</sub> was estimated using linear regression models.</p><p><strong>Results: </strong>Increased FDG activity in cervical nodes was observed in 136/191 studies (71%). The mean SUVmax<sub>CLN</sub> was 2.2 ± 1.3. Ipsilateral palatine tonsil SUVmax, mean liver uptake, and treatment status were all statistically significant predictors of SUVmax<sub>CLN</sub>. However, in multivariate regression analysis, only ipsilateral palatine tonsil SUVmax was found to be significant. In addition, SUVmax<sub>CLN</sub> was greater than the mean liver uptake in 50% of all studies. This proportion was higher in younger children, reaching 77% of studies of children younger than six years.</p><p><strong>Conclusion: </strong>SUVmax in ipsilateral palatine tonsil is a strong predictor of the maximal uptake value of non-malignant cervical lymph nodes in children. The intensity of uptake in non-malignant cervical lymph nodes is frequently higher than liver uptake in children, and this tendency increases for younger patients.</p><p><strong>Trial was registered: </strong>In the internal hospital registry under TRN 0209-22-HMO on date 23.04.2022.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-28DOI: 10.1186/s13550-024-01113-6
Silvano Marchiori, François Cousin, Iraklis Papadopoulos, Claire Bernard, Marie Thys, Bernard De Prijck, Michelle Pirotte, Anne-Françoise Donneau, Roland Hustinx, Jo Caers, Nadia Withofs
Background: 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography combined with low-dose computed tomography (PET/CT) can be used at diagnosis to identify myeloma-defining events and also provides prognostic factors. The aim of this study was to assess the prognostic significance of baseline [18F]FDG PET/CT visual IMPeTUs (Italian myeloma criteria for PET Use)-based parameters and/or total metabolic tumor volume (TMTV) in a single-center population of patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation.
Methods: Patients with MM who underwent a baseline [18F]FDG PET/CT were retrospectively selected from a large internal database of the University Hospital of Liege (Liege, Belgium). Initially, all PET/CT images were visually analyzed using IMPeTUs criteria, followed by delineation of TMTV using a semi-automatic lesion delineation workflow, including [18F]FDG-positive MM focal lesions (FL) with an absolute SUV threshold set at 4.0. In a first step, to ensure PET/CT scans accurate reporting, the agreement between two nuclear medicine physicians with distinct experience was assessed. In the second step, univariable and multivariable analyses were conducted to determine the prognostic significance of [18F]FDG PET/CT parameters on progression free survival (PFS) and overall survival (OS), respectively.
Results: A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [18F]FDG PET/CT parameters, a high number of delineated volumes of interest (VOI) using the SUV4.0 threshold was the only independent prognostic factor associated with PFS [HR (95% CI): 1.03 (1.004-1.05), P = 0.019] while a high number of FL (n > 10; F group 4) was the only independent prognostic factor associated with OS [HR (95% CI): 19.10 (1.90-191.95), P = 0.01].
Conclusion: Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [18F]FDG-avid tumor burden, is an independent prognostic factor for OS. The prognostic value of the TMTV delineated using a SUV4.0 threshold was not significant. Nevertheless, the count of delineated [18F]FDG-avid lesions VOI using a SUV4.0 threshold was an independent prognostic factor for PFS.
{"title":"Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [<sup>18</sup>F]FDG PET/CT in patients with newly diagnosed multiple myeloma.","authors":"Silvano Marchiori, François Cousin, Iraklis Papadopoulos, Claire Bernard, Marie Thys, Bernard De Prijck, Michelle Pirotte, Anne-Françoise Donneau, Roland Hustinx, Jo Caers, Nadia Withofs","doi":"10.1186/s13550-024-01113-6","DOIUrl":"10.1186/s13550-024-01113-6","url":null,"abstract":"<p><strong>Background: </strong>2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose ([<sup>18</sup>F]FDG) positron emission tomography combined with low-dose computed tomography (PET/CT) can be used at diagnosis to identify myeloma-defining events and also provides prognostic factors. The aim of this study was to assess the prognostic significance of baseline [<sup>18</sup>F]FDG PET/CT visual IMPeTUs (Italian myeloma criteria for PET Use)-based parameters and/or total metabolic tumor volume (TMTV) in a single-center population of patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation.</p><p><strong>Methods: </strong>Patients with MM who underwent a baseline [<sup>18</sup>F]FDG PET/CT were retrospectively selected from a large internal database of the University Hospital of Liege (Liege, Belgium). Initially, all PET/CT images were visually analyzed using IMPeTUs criteria, followed by delineation of TMTV using a semi-automatic lesion delineation workflow, including [<sup>18</sup>F]FDG-positive MM focal lesions (FL) with an absolute SUV threshold set at 4.0. In a first step, to ensure PET/CT scans accurate reporting, the agreement between two nuclear medicine physicians with distinct experience was assessed. In the second step, univariable and multivariable analyses were conducted to determine the prognostic significance of [<sup>18</sup>F]FDG PET/CT parameters on progression free survival (PFS) and overall survival (OS), respectively.</p><p><strong>Results: </strong>A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [<sup>18</sup>F]FDG PET/CT parameters, a high number of delineated volumes of interest (VOI) using the SUV4.0 threshold was the only independent prognostic factor associated with PFS [HR (95% CI): 1.03 (1.004-1.05), P = 0.019] while a high number of FL (n > 10; F group 4) was the only independent prognostic factor associated with OS [HR (95% CI): 19.10 (1.90-191.95), P = 0.01].</p><p><strong>Conclusion: </strong>Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [<sup>18</sup>F]FDG-avid tumor burden, is an independent prognostic factor for OS. The prognostic value of the TMTV delineated using a SUV4.0 threshold was not significant. Nevertheless, the count of delineated [<sup>18</sup>F]FDG-avid lesions VOI using a SUV4.0 threshold was an independent prognostic factor for PFS.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}